SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
SEC Accession No. 0001011438-18-000076
Filing Date
2018-02-13
Accepted
2018-02-13 17:14:35
Documents
1
Group Members
AKDI, L.P.BRATTON CAPITAL MANAGEMENT, L.P.BRATTON CAPITAL, INC.CRESTLINE INVESTORS, INC.CRESTLINE MANAGEMENT, L.P.CRESTLINE SI (GP), L.P.NEURO LINE PARTNERS, L.P.

Document Format Files

Seq Description Document Type Size
1 form_sc13g-denali.htm SC 13G 206482
  Complete submission text file 0001011438-18-000076.txt   208077
Mailing Address 201 MAIN STREET SUITE 1900 FORT WORTH TX 76102
Business Address
BRATTON DOUGLAS K (Filed by) CIK: 0001281933 (see all company filings)

Type: SC 13G

Mailing Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Subject) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-90223 | Film No.: 18604821
SIC: 2836 Biological Products, (No Diagnostic Substances)